EndoTool vs Glytec (2026)
The inpatient insulin dosing decision, and it is one of the few in this index where both options are FDA cleared Class II software and the comparison is therefore between two regulated devices rather than between two claims. Glucommander is the incumbent by a wide margin, cleared for intravenous insulin since 2006 and subcutaneous since 2010, deployed more widely than anything else of its kind, with the deeper published evidence base across hyperglycaemia, hypoglycaemia and length of stay. EndoTool covers the same clinical span including the intravenous to subcutaneous transition and paediatrics, and its control algorithm is described in the independent literature in more detail than either vendor publishes about itself. Neither publishes a security attestation, a business associate posture or any subgroup performance data, which in a product that computes an insulin dose is the gap worth pressing hardest.
- Coverage inside inpatient glycemic management is complete and cleared: intravenous dosing, the transition from intravenous to subcutaneous, and subcutaneous dosing, in adult and paediatric patients.
- The algorithm is model predictive control with a nonlinear dosing equation individualised to the patient, which independent literature describes in more detail than the vendor does, so the mechanism is knowable from outside.
- It is the direct alternative in a segment with only two credible occupants, which matters at renewal: a hospital with one incumbent has exactly one comparable place to go.
- The longest clearance history in the segment, cleared as Class II software for intravenous insulin since 2006 and subcutaneous since 2010, in patients aged two and over, and the most widely deployed system of its kind in American hospitals.
- The deepest published evidence base in glycemic management, spanning reductions in both hyperglycaemia and hypoglycaemia, time to target and length of stay.
- Bidirectional and clinically deep record system integration with major platforms, plus a command centre giving system wide visibility across sites rather than one unit at a time.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. EndoTool and Glytec are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | EndoTool | Glytec |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2006 | 2006 |
| Headquarters | Charlotte, North Carolina, United States | Waltham, Massachusetts, United States |
| Website | monarchmedtech.com | glytec.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards EndoTool its top capability grade on FDA and Regulatory Status. Set against Glytec, EndoTool grades higher on AI Centrality and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including Model Supply Chain Disclosure, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Glytec its top capability grade on FDA and Regulatory Status. Set against EndoTool, Glytec grades higher on Model Supply Chain Disclosure and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose EndoTool or Glytec?
On the axes where the AI Health Index separates them, EndoTool grades higher on AI Centrality and AI Liability and Recourse, and Glytec grades higher on Model Supply Chain Disclosure and Clinical and Operational Evidence. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do EndoTool and Glytec differ most?
The widest separation the AI Health Index records between EndoTool and Glytec is on AI Centrality, where EndoTool grades C and Glytec grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do EndoTool and Glytec grade the same?
The AI Health Index grades EndoTool and Glytec the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have EndoTool and Glytec not disclosed?
At the last review, at least one of EndoTool and Glytec published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both vendors publish essentially nothing on the axes a security review examines. Neither has a located SOC 2 report, HITRUST certification, ISO 27001, trust centre, penetration testing cadence or vulnerability disclosure programme, and neither publishes a HIPAA statement or business associate agreement terms. Neither publishes performance by age, sex, race, body habitus, renal function or diabetes type, which matters because insulin requirements vary with all of them.
Independent peer reviewed reviews classify both systems as rule based or proportional integral derivative control with static parameters rather than learned models, so neither is AI in the sense the category label implies, and neither publishes pricing.